Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

72.00 -1.34 (-1.83%)
Streaming Delayed Price Updated: 2:57 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
Earnings Scheduled For May 10, 2021 ↗
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
News headline image
Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 Guidance ↗
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q2 revenue of $136.5 million compared to $55.2 million a year ago, beating the consensus of $103.16 million.... 
Via Benzinga
News headline image
Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript ↗
HALO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Halozyme Therapeutics: Q2 Earnings Insights ↗
Shares of Halozyme Therapeutics (NASDAQ:HALO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 247.37% over the... 
Via Benzinga
News headline image
Analyzing Halozyme Therapeutics's Unusual Options Activity ↗
On Friday, shares of Halozyme Therapeutics (NASDAQ:HALO) saw unusual options activity. After the option alert, the stock price moved down to $42.55. Sentiment: BEARISH Option... 
Via Benzinga
News headline image
Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma ↗
The FDA has approved Janssen Biotech Inc's, a unit of Johnson & Johnson (NYSE: JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for multiple... 
Via Benzinga
News headline image
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal ↗
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
News headline image
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
From ViiV Healthcare
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021 ↗
Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Nymox Pharmaceutical (NASDAQ:NYMX... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021 ↗
Upgrades B of A Securities upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Neutral to Buy. In the first quarter, Kosmos Energy showed an EPS of $0.08,... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021 ↗
Upgrades For CEVA Inc (NASDAQ:CEVA), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first quarter, CEVA had an EPS of $0.01, compared to year... 
Via Benzinga
News headline image
Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript ↗
HALO earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
News headline image
Earnings Outlook for Halozyme Therapeutics ↗
On Monday, May 10, Halozyme Therapeutics (NASDAQ:HALO) will release its latest earnings report. Here is Benzinga's outlook for the company. Net Income, Earnings, And Earnings Per... 
Via Benzinga
News headline image
Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory ↗
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. Krystal Biotech stock fits that bill. 
Via Investor's Business Daily
News headline image
Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
Cel-Sci shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Biotech Applied Molecular Transport Stock Earns Relative Strength Rating Upgrade ↗
On Tuesday, Applied Molecular Transport stock reached an important technical milestone, seeing its Relative Strength Rating jump to 91 from 87. 
Via Investor's Business Daily
News headline image
Arvinas Stock Clears Technical Benchmark With 80-Plus Relative Strength Rating ↗
Arvinas shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84. 
Via Investor's Business Daily
News headline image
Scholar Rock Stock Shows Market Leadership With Healthy Jump To 83 RS Rating ↗
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. Scholar Rock stock fits that bill. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.